Abacavir and Cardiovascular Risk in HIV‐Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role? | Zendy

Giulia Marchetti | Zendy; Maddalena Casana | Zendy; Camilla Tincati | Zendy; Giusi Maria Bellistrì | Zendy; Antonella d’Arminio Monforte | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abacavir and Cardiovascular Risk in HIV‐Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role?

Author(s) -

Giulia Marchetti,

Maddalena Casana,

Camilla Tincati,

Giusi Maria Bellistrì,

Antonella d’Arminio Monforte

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/593110

Subject(s) - abacavir , medicine , hyperactivation , immunology , lentivirus , virology , human immunodeficiency virus (hiv) , lymphocyte , sida , viral disease , viral load , antiretroviral therapy

Purpose of the study The association between abacavir exposure and cardiovascular disease (CVD) in HIV-infected patients is currently intensely debated. Recently, the D:A:D Study Group described increased myocardial infarction risk in patients with current/recent abacavir exposure, while repository data from GlaxoSmithKline clinical trials failed to find any association. Given the association between lymphocyte hyperactivation and CVD, and the major role of T-cell hyperactivation in HIV/AIDS, the purpose of our study was to investigate T-cell immunephenotype and proinflammatory cytokines kinetics in HIV-infected patients receiving abacavir-containing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research